This year, beauty technology company Cutera filed for a prepackaged Chapter 11 bankruptcy on March 5 to reduce its debt by ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the market got it wrong on HIMS stock.

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive’s reaffirmation that the company will continue to offer ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper compounded versions of GLP-1 weight-loss drugs, despite the ...

Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the U.S. company is using 'deceptive marketing' to sell copycat versions of its obesity ...

The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.

Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after Novo Nordisk A/S abruptly ended its distribution partnership.

Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds Novo Nordisk and Hims & Hers just announced a partnership in April.